Professor Marie Ranson (PhD, University of Sydney, 1990) is a tenured Teaching and Research Academic at the University of Wollongong. She has a significant track record of research in cancer cell and molecular biology, with particular expertise in cancer migration, invasion and metastasis. She has extensive experience in the use of in vitro, ex vivo and animal models for cancer drug discovery and targeting as well as improved delivery of chemotherapeutic drugs. Prof Ranson has published over 85 peer-reviewed journal articles, attracted several national competitive grants totalling over $10,000,000, and has been granted patents in her drug development portfolio. In particular, she led the preclinical development of chemotherapy agent Deflexifol, which has been licenced to FivePhusion Pty Ltd who completed Phase 1 human trials in June 2017. Prof Ranson is also the Illawarra area lead and CI of the CINSW-funded CONCERT Translational Cancer Research Centre to build research capacity in targeted therapies and is a member of a number of professional societies and committees.
PhD, University of Sydney
BSc (Hons), University of NSW